ARTICLE | Finance
As valuation swells above $380M, Syncona-backed Gyroscope draws $148M series C, mulls listing
Ophthalmic play could be third gene therapy IPO from Syncona’s portfolio
March 26, 2021 10:54 PM UTC
Gene therapy developer Gyroscope has another $148 million to fuel further clinical testing of its lead program for age-related macular degeneration — and the Syncona-backed, U.K.-based company could soon raise more via a U.S. listing.
Forbion Capital Partners led the round via its Growth Opportunities Fund, while founding investor Syncona Ltd. (LSE:SYNC) supplied $42.3 million...